Absci Corporation will report its business updates and financial and operating results for the second quarter of 2026 after market close on Tuesday, August 11, 2026. The clinical-stage biopharmaceutical company, which uses generative AI to design therapeutics, scheduled the release to provide investors with an update on its performance and strategic direction.

Absci management will webcast a conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on the same day. The call will cover business developments, financial and operating results, and the company's outlook. Participants can access the live audio on the company’s investor relations website at investors.absci.com, where a replay will be available afterward.

Key Event Details

Absci focuses on drug discovery through its Integrated Drug Creation™ platform, combining AI models with synthetic biology. The company is advancing its own pipeline, including ABS-201™, a therapeutic for androgenetic alopecia and endometriosis.

Absci Corporation has priced a $100 million underwritten public offering to fund the clinical advancement of ABS-201, its AI-designed therapeutic program for androgenetic alopecia and endometriosis, following positive interim Phase 1 results. The offering consists of 13.5 million shares of common stock priced at $7.41 per share, with gross proceeds expected to reach approximately $100 million before deducting underwriting discounts and commissions. All shares are being sold by Absci, and the offering is anticipated to close on or about June 25, 2026.

The clinical-stage biopharmaceutical company reported that the early-stage trial findings demonstrated a favorable safety, pharmacokinetic, and immunogenicity profile for ABS-201. The ongoing Phase 1 study is a randomized, double-blind, placebo-controlled trial assessing the safety and pharmacokinetics of ABS-201 in healthy volunteers with and without androgenetic alopecia. Interim data include 32 healthy adults enrolled across four single ascending dose cohorts evaluating intravenous doses of 150 mg, 450 mg, 900 mg, and 1,800 mg.

According to blinded aggregate data through the June 8, 2026, cutoff, ABS-201 was generally well tolerated with no serious adverse events reported. Most treatment-emergent adverse events were mild, with a single moderate headache in one participant deemed unlikely to be related to treatment. Pharmacokinetic findings indicated that ABS-201 may have a half-life of at least 65 days, potentially supporting dosing two or three times over a six-month period, subject to confirmation in ongoing follow-up.

ABS-201 Clinical Trial Details

Absci plans to continue evaluating ABS-201 in the ongoing multiple ascending dose portion of the HEADLINE study in androgenetic alopecia patients and intends to begin a Phase 2 trial in endometriosis later this year. The financing includes strategic investment from Eli Lilly & Company alongside financial institutions such as Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm.

Absci intends to allocate the net proceeds primarily to the development of ABS-201, an anti-PRLR antibody program, as well as for working capital and general corporate purposes. Cash, cash equivalents, and marketable securities as of March 31, 2026, were $125.7 million, which Absci expected to provide a cash runway into the first half of 2028. Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities are acting as joint book-running managers for the offering.